^
    Back
    Association details:
    Biomarker:ALK C1156Y + ALK L1198F
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    N Engl J Med
    Title:

    Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

    Excerpt:
    After the patient had a response to crizotinib a second time, relapse occurred and another biopsy specimen was obtained. Snapshot NGS testing of the crizotinib-resistant specimen showed that the ALK L1198F mutation was no longer detectable. These findings are consistent with effective suppression of the C1156Y–L1198F subclone by crizotinib.
    DOI:
    10.1056/NEJMoa1508887